Recombinant human erythropoietin

ApprovedSmall molecule

Recombinant human erythropoietin is one of 383 small molecule programs targeting Cerebral Palsy. It is currently in Approved.

Indications

Total Trials

Active Trials

382

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

LymphomaActive, not recruiting

Brain InjuryActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

AnemiaActive, not recruiting

EncephalopathyActive, not recruiting

Acute Kidney InjuryActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Cerebral PalsyPreclinical

Active, not recruiting

LymphomaPhase 3

Active, not recruiting

Brain InjuryApproved

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 1/Phase 2

Active, not recruiting

AnemiaPhase 2

Active, not recruiting

EncephalopathyPhase 1/Phase 2

Active, not recruiting

Acute Kidney InjuryApproved

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 1/Phase 2

Active, not recruiting

Chronic Kidney DiseaseApproved

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Recombinant human erythropoietin

Amgen

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 10

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Not yet recruiting

Poor Graft Function

NCT05669079

Phase 3Not yet recruiting

Poor Graft Function

NCT05907499

Post-ApprovalNot yet recruiting

Sarcopenia

NCT07162090

Clinical

Trials by Indication[1]

Erythropoietin5 trials

Does Erythropoietin Improve Outcome in Very Preterm Infants?

Completed·SSwiss Neonatal Network·Phase 2·NCT00413946·420 enrolled

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT00144495·104 enrolled

Identification of New Serum Markers for Detection of Abuse With Erythropoietin

Completed·UUniversity of Aarhus·N/A·NCT01320449·35 enrolled

Show 2 more trials

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT00144482·122 enrolled

Can Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive?

Unknown status·RRigshospitalet, Denmark··NCT00265486·12 enrolled

Anemia4 trials

The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia

Unknown status·—·Phase 1·NCT03683810·50 enrolled

Treatment for Patients Suffering From Anemia Due to Chemotherapy

Completed· Amgen logo

Amgen·Phase 2·NCT00120692

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

Completed· Amgen logo

Amgen·Phase 2·NCT00121030

Show 1 more trial

A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

Unknown status·AAngde Biotech Pharmaceutical Co., Ltd.·Phase 2·NCT05629598·150 enrolled

Neuropathy2 trials

Traumatic Optic Neuropathy Treatment Trial 2

Completed·IIran University of Medical Sciences·Phase 3·NCT03308448·93 enrolled

Traumatic Optic Neuropathy Treatment Trial (TONTT)

Completed·TTehran University of Medical Sciences·Phase 1/2·NCT01783847·117 enrolled

Poor Graft Function2 trials

Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05669079·100 enrolled

Decitabine for Poor Graft Function Post Allo-HSCT

Not yet recruiting·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT05907499·76 enrolled

Lymphoma1 trial

Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04910594·130 enrolled

13 more indications

Encephalopathy1 trial

Neurological Outcome After Erythropoietin Treatment for Neonatal Encephalopathy

Completed·ZZhengzhou University·Phase 1/2·NCT00808704·167 enrolled

Brain Injury1 trial

Effect of Erythropoietin on Preterm Brain Injury

Completed·—·Phase 4·NCT02036073·490 enrolled

Neurodevelopment1 trial

Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants

Unknown status·HHuiqing Sun·N/A·NCT02745990·440 enrolled

Acute Kidney Injury1 trial

Prevention of Acute Kidney Injury by Erythropoietin in Thoracic Aorta Surgery With Hypothermic Cardiac Arrest

Completed·YYonsei University·Phase 4·NCT01369732·66 enrolled

Pregnancy1 trial

Intravenous Treatment of Anemia in Pregnancy

Completed·UUniversity of Zurich·Phase 4·NCT03317210·50 enrolled

Non-Small Cell Lung Cancer1 trial

Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy

Completed· Amgen logo

Amgen·Phase 2·NCT00120679

Amyotrophic Lateral Sclerosis1 trial

Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis

Unknown status·HHanyang University Seoul Hospital·Phase 1/2·NCT03835507·64 enrolled

Sarcopenia1 trial

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients

Not yet recruiting·TTianjin Medical University General Hospital·Phase 4·NCT07162090·60 enrolled

Myelodysplastic Syndromes1 trial

A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00910858·40 enrolled

Injury1 trial

Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants

Unknown status·UUniversity of Zurich·Phase 3·NCT02076373·120 enrolled

Cerebral Palsy1 trial

Safety and Efficacy of Multiple EPO Injections in Children With Cerebral Palsy

Completed·—··NCT03303573·164 enrolled

Chronic Kidney Disease1 trial

Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin for Treatment of Anemia in Children With Chronic Kidney Disease

Completed·RRufaida Mazahir·Phase 4·NCT04959578·50 enrolled

Unspecified1 trial

Tracing Changed Production of Red Blood Cells

Completed·UUniversity of Copenhagen·N/A·NCT05833477·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Recombinant human erythropoietin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant human erythropoietin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant human erythropoietin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Amgen

Recombinant human erythropoietin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Erythropoietin5 trials

Anemia4 trials

Neuropathy2 trials

Poor Graft Function2 trials

Lymphoma1 trial

Encephalopathy1 trial

Brain Injury1 trial

Neurodevelopment1 trial

Acute Kidney Injury1 trial

Pregnancy1 trial

Non-Small Cell Lung Cancer1 trial

Amyotrophic Lateral Sclerosis1 trial

Sarcopenia1 trial

Myelodysplastic Syndromes1 trial

Injury1 trial

Cerebral Palsy1 trial

Chronic Kidney Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News